DCPS as an m7G-Related Gene Regulating Epithelial Function in Diabetic Foot Ulcers

Study Background and Research Question

Chronic nonhealing wounds, particularly diabetic foot ulcers (DFUs), represent a significant complication of diabetes mellitus, affecting up to 34% of adult patients and contributing to morbidity worldwide. Healing in DFUs is characteristically delayed, and the underlying molecular mechanisms remain incompletely defined. Recent interest has focused on RNA modifications, especially N7-methylguanosine (m7G) methylation, which governs RNA stability and gene expression but whose relevance in chronic wound pathology is largely unexplored.

The central research question addressed by Xiao et al. (World J Diabetes 2025) is whether m7G-related genes, specifically the decapping scavenger enzyme (DCPS), serve as functional biomarkers and molecular regulators in DFU pathogenesis. By characterizing the expression and functional impact of DCPS in epithelial cells from DFU lesions, the study aims to clarify the link between RNA modification enzymes and wound healing dynamics.

Key Innovation from the Reference Study

The primary innovation of this work lies in identifying DCPS, a decapping scavenger enzyme implicated in m7G cap metabolism, as a diagnostic and mechanistic biomarker for DFUs. The study moves beyond correlative gene expression profiling by incorporating functional genomics and cell biology to demonstrate that DCPS is not only reduced in DFU tissue but also actively regulates epithelial cell proliferation, migration, and cell cycle progression. This positions DCPS as both a potential diagnostic marker (with high sensitivity and specificity) and a therapeutic target for improving wound healing in diabetic patients, a novel insight in the context of chronic ulcer management.

Methods and Experimental Design Insights

The research adopts a multi-stage experimental strategy integrating bioinformatics, molecular validation, and cellular functional assays:

• Bioinformatic Analysis: Differential gene expression and weighted gene coexpression network analysis (WGCNA) were performed on transcriptomic datasets from DFU tissues to identify m7G-associated candidate genes.
• Hub Gene Identification: Intersection analysis between m7G-related and DFU-altered gene sets pinpointed DCPS. Receiver operating characteristic (ROC) curve analysis evaluated its diagnostic performance, yielding an area under the curve (AUC) of 0.98–0.99 (reference).
• Molecular Validation: Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunofluorescence staining confirmed significantly decreased DCPS expression in wound tissue from DFU patients and diabetic mouse models.
• Cellular Functional Assays: In vitro, normal human epidermal keratinocytes (NHEKs) were subjected to DCPS knockdown. Effects on cell proliferation, cell cycle progression, apoptosis, and migration were quantified via flow cytometry, western blotting (for cyclin D1 and CDK6), Transwell migration assays, and scratch wound assays.

Protocol Parameters

• Gene Expression Analysis: RNA was extracted from wound skin and analyzed by qRT-PCR, with normalization to housekeeping genes and validation by immunofluorescence imaging.
• DCPS Knockdown: NHEKs were transfected with specific siRNAs targeting DCPS, and knockdown verified 48–72 hours post-transfection.
• Cell Proliferation and Cycle Analysis: Flow cytometry was employed to quantify S-phase entry and apoptosis rates, often leveraging DNA synthesis detection assays compatible with click chemistry labeling.
• Migration Assays: Transwell and scratch assays were conducted 24–48 hours post-knockdown to assess epithelial cell motility.

Core Findings and Why They Matter

Weighted gene coexpression network and differential expression analyses highlighted significant enrichment of methylation-related processes in DFU tissues, with DCPS emerging as a top hub gene. Clinical tissue analysis revealed that DCPS expression is markedly reduced in both human DFU samples and diabetic mouse models. ROC curve analysis demonstrated DCPS's strong diagnostic potential (AUC 0.98–0.99), indicating high discriminatory power between DFU and control tissues (reference).

Functional studies showed that knockdown of DCPS in keratinocytes led to:

• Reduced expression of cyclin D1 and CDK6, key cell cycle regulators
• Impaired S-phase progression and cell proliferation
• Increased apoptosis
• Significantly diminished cell migration capacity

These findings establish a mechanistic link between m7G RNA cap metabolism and epithelial dysfunction in chronic wounds. They also suggest that restoring DCPS activity or targeting m7G-related pathways may promote wound healing—an important consideration given the current lack of effective biomarkers and therapeutics for DFU.

Comparison with Existing Internal Articles

The reference study’s cell cycle and proliferation assays closely align with workflows described in internal technical guides for click chemistry-based DNA synthesis detection. For instance, the EdU Flow Cytometry Assay Kits (Cy5) article details the use of 5-ethynyl-2'-deoxyuridine and copper-catalyzed azide-alkyne cycloaddition (CuAAC) for sensitive S-phase detection, a methodological advance over classical BrdU protocols. The Technical Guide discusses the importance of gentle, denaturation-free detection compatible with multiplexed flow cytometry, mirroring the approach required for complex cellular phenotyping in DFU models. Furthermore, the mechanistic insights article contextualizes how such platforms enable biomarker validation and cell cycle dissection in disease-relevant settings, directly supporting the reference study’s experimental rationale. Collectively, these resources illustrate that cutting-edge flow cytometry cell proliferation assays are integral for dissecting the molecular basis of impaired healing in chronic wounds and for validating candidate biomarkers such as DCPS.

Limitations and Transferability

While the study robustly identifies DCPS as a candidate biomarker and functional regulator, several limitations are noteworthy. The mechanistic data are predominantly derived from in vitro NHEK models, which, despite their relevance, may not fully capture the complexity of the diabetic wound environment in vivo. Additionally, while DCPS knockdown effects on proliferation and migration are clear, the downstream signaling pathways mediating these effects require further elucidation. The generalizability of DCPS as a biomarker across different wound types or stages also awaits validation in larger, independent patient cohorts. Nonetheless, the high diagnostic accuracy and mechanistic plausibility support the translational potential of targeting m7G-related pathways in chronic wound management.

Research Support Resources

For researchers seeking to replicate or extend the reference study’s cell proliferation and cell cycle analyses, the EdU Flow Cytometry Assay Kits (Cy5) (SKU K1078) offer a sensitive and reliable platform for click chemistry DNA synthesis detection. These kits utilize copper-catalyzed azide-alkyne cycloaddition (CuAAC) to label nascent DNA in proliferating cells, obviating harsh denaturation steps and enabling high-fidelity flow cytometry cell proliferation assays. Such technologies are well-suited for dissecting S-phase dynamics and validating cell cycle biomarkers—including those highlighted in the DCPS-m7G axis—across a variety of research contexts.